Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-27 | Direct | 123,600 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 123,600 · Balance 123,600 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed Jun 1, 2026 20:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantDirector Stock Option (Right to Buy) · Derivative | 123,600 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001902958-26-000004 · ownership.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,600 Underlying: Class A Common Stock · 123,600 shares Expires 2036-05-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:55 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001415889-25-015037 · form4-05302025_090554.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2035-05-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 17,708 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-24-137318 · ownership.xml · derivative · entry 4 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,037 Underlying: Class A Common Stock · 17,708 shares Expires 2032-01-02 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $17.00 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vested on January 3, 2023; and 1/36th of the shares subject to the option vest monthly over the following two years. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,708 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137318 · ownership.xml · derivative · entry 3 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 17,708 shares Expires 2032-01-02 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $17.00 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vested on January 3, 2023; and 1/36th of the shares subject to the option vest monthly over the following two years. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-24-137318 · ownership.xml · derivative · entry 2 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137318 · ownership.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066579 · ownership.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 17,708 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071466 · ownership.xml · derivative · entry 4 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,708 Underlying: Class A Common Stock · 17,708 shares Expires 2032-01-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on January 3, 2023; and 1/36th of the shares subject to the option vest monthly over the following two years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,708 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0000950170-23-071466 · ownership.xml · derivative · entry 3 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,329 Underlying: Class A Common Stock · 17,708 shares Expires 2032-01-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F3 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on January 3, 2023; and 1/36th of the shares subject to the option vest monthly over the following two years. F3 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071466 · ownership.xml · derivative · entry 2 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-23-071466 · ownership.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| May 25, 2023 Filed May 31, 2023 00:07 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-23-033046 · doc4.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| May 25, 2022 Filed May 27, 2022 12:30 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 16,112 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0000899243-22-019856 · doc4.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,112 Underlying: Class A Common Stock · 16,112 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 23:55 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 49,037 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001967 · doc4.xml · derivative · entry 1 Rometty Lisa Ann · CIK 0001902958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,037 Underlying: Class A Common Stock · 49,037 shares Expires 2032-01-03 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on January 3, 2023; and 1/36th of the shares subject to the option vest monthly thereafter over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.